ProPhase Labs (NASDAQ:PRPH – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Insider and Institutional Ownership
9.4% of ProPhase Labs shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for ProPhase Labs and TransCode Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProPhase Labs | 1 | 0 | 0 | 0 | 1.00 |
| TransCode Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProPhase Labs | $5.06 million | 0.12 | -$53.36 million | ($3.90) | -0.03 |
| TransCode Therapeutics | N/A | N/A | -$34.66 million | ($50.33) | -0.10 |
TransCode Therapeutics has lower revenue, but higher earnings than ProPhase Labs. TransCode Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ProPhase Labs and TransCode Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProPhase Labs | -825.01% | -482.05% | -88.90% |
| TransCode Therapeutics | N/A | -875.35% | -50.36% |
Risk & Volatility
ProPhase Labs has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
Summary
ProPhase Labs beats TransCode Therapeutics on 6 of the 10 factors compared between the two stocks.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
About TransCode Therapeutics
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
